Korlym: New drug to treat Cushing's Disease

I know several folks who have recently started taking the new FDA-approved drug, Korlym, to treat Cushing's Disease.  Korlym is a new name for the "old" drug mifepristone and was developed by Corcept Therapeutics Incorporated. 

Korlym blocks the activity of cortisol and is proven to reduce high blood sugar (hyperglycemia), a key symptom of Cushing's. Korlym has a unique way of working. Instead of reducing cortisol levels, it blocks the action of cortisol, thus preventing the effects of excess cortisol.¹

Korlym has many side effects and cannot be taken by everyone.  Once the patient stops taking Korlym, she will continue to have Cushing's.  The biologic half-life of Korlym is approximately 85 hours.  If a patient suffers adrenal insufficiency or crisis, massive amounts of hydrocortisone or dexamethasone are needed to alleviate these and will have to be continued for the duration of the drug in his system.

To follow a patient who has just started taking Korlym, you will find her blog here:  Cushing's Disease